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Low Physical Activity and Risk of Cardiovascular and
All-Cause Mortality in Renal Transplant Recipients
Dorien M. Zelle,* Eva Corpeleijn,† Ronald P. Stolk,† Mathieu H.G. de Greef,‡ Rijk O.B. Gans,§
Jaap J. Homan van der Heide,* Gerjan Navis,* and Stephan J.L. Bakker§
Summary
Background and objectives Low physical activity (PA) is a risk factor for mortality in the general popula-
tion. This is largely unexplored in renal transplant recipients (RTRs). We studied whether PA is associated
with cardiovascular and all-cause mortality in a prospective cohort of RTR.
Design, setting, participants, & measurements Between 2001 and 2003, 540 RTRs were studied (age, 51  12
years; 54% male). PA was assessed using validated questionnaires (Tecumseh Occupational Activity Ques-
tionnaire and the Minnesota Leisure Time Physical Activity Questionnaire). Cardiovascular and all-cause
mortality were recorded until August 2007.
Results Independent of age, PA was inversely associated with metabolic syndrome, history of cardiovascu-
lar disease, fasting insulin, and triglyceride concentration, and positively associated with kidney function
and 24-hour urinary creatinine excretion (i.e., muscle mass). During follow-up for 5.3 years (range, 4.7 to 5.7
years), 81 RTRs died, with 37 cardiovascular deaths. Cardiovascular mortality was 11.7, 7.2, and 1.7%, re-
spectively, according to gender-stratified tertiles of PA (P  0.001). All-cause mortality was 24.4, 15.0, and
5.6% according to these tertiles (P  0.001). In Cox regression analyses, adjustment for potential confound-
ers including history of cardiovascular disease, muscle mass, and traditional risk factors for cardiovascular
disease did not materially change these associations.
Conclusions Low PA is strongly associated with increased risk for cardiovascular and all-cause mortality in
RTRs. Intervention studies are necessary to investigate whether PA improves long-term survival after renal
transplantation.
Clin J Am Soc Nephrol 6: 898–905, 2011. doi: 10.2215/CJN.03340410
Introduction
The incidence and prevalence of cardiovascular dis-
ease (CVD) are estimated to be four to six times
higher in renal transplant recipients (RTRs) than in
the general population (1,2). Classical CVD risk fac-
tors such as dyslipidemia, hypertension, and obesity,
which commonly coexist as the metabolic syndrome
(MS), contribute to this excess in CVD (3,4). Other
factors more specific for transplantation, such as use
of immunosuppressive drugs and muscle wasting,
might also be relevant to this high-risk profile. How-
ever, the influence of physical activity (PA) on CVD
and mortality is largely unexplored.
In the general population, PA is associated with a
lower prevalence and incidence of cardiovascular
(CV) risk factors, including hypertension, type 2 dia-
betes mellitus, obesity, and dyslipidemia (5,6). It has
also been established that low PA predicts CVD and
mortality in the general population (5,7,8).
In advanced chronic kidney disease (CKD), PA lev-
els are low and remain low after renal transplantation
(9,10). Most RTRs enhance their level of PA slightly
immediately after transplantation, although com-
pared with the general population, cardiorespiratory
fitness in RTRs remains low (11). These low levels of
PA can be explained by several factors. Muscle
strength is impaired in RTRs compared with controls
(10). Use of corticosteroids as immunosuppressive
therapy and impaired renal function may contribute
to an altered body composition, characterized by
higher fat and lower muscle mass (12). Additionally,
disuse of muscle by lack of PA can result in muscle
atrophy (13), which is a risk factor for mortality in both
RTRs and the general population (12,14).
It is not known whether low levels of PA are related
to risk factors for CVD in RTRs. Likewise, it is not
known whether low PA in RTRs translates into in-
creased risk for CV and all-cause mortality.
We aimed to study cross-sectionally whether PA
level is associated with CV risk factors and MS in
RTRs. We further aimed to prospectively investigate
in these patients whether PA is associated with CV
and all-cause mortality. Finally, we sought to analyze
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In this prospective cohort study, all RTRs who visited
the outpatient clinic at the University Medical Centre Gro-
ningen between August 2001 and July 2003 were invited to
participate. Eligible for participation were all adult RTRs
with transplant duration 1 year and with functioning
allograft at time of invitation. The group that did sign
informed consent was comparable with the group that did
not sign informed consent with respect to age, gender,
body mass index, serum creatinine, creatinine clearance,
and proteinuria. In patients with fever or other signs of
infection (e.g., complaints of upper respiratory tract infec-
tion or urinary tract infection), baseline visits were post-
poned until symptoms had resolved. Patients with overt
congestive heart failure and patients diagnosed with can-
cer other than cured skin cancer were not considered eli-
gible for the study. Data on PA were available in 547
patients; 7 patients with amputations were excluded be-
cause of the possible incapability of being physically ac-
tive. Full details on the study design have been previously
reported (15). The Institutional Review Board approved
the study protocol (METc 2001/039).
Endpoints of the study
The primary endpoints of the study were recipient CV
and all-cause mortality. The continuous surveillance sys-
tem of the outpatient program ensures up-to-date informa-
tion on patient status and cause of death. CV and all-cause
mortality was recorded until August 2007. We contacted
general practitioners or referring nephrologists in case the
status of a patient was unknown. Cause of death was
obtained by linking the number of the death certificate to
the primary cause of death as coded by a physician from
the Central Bureau of Statistics. Causes of death were
coded according to the International Classification of Dis-
eases, 9th revision (ICD-9) (16). CV death was defined as
deaths in which the principal cause of death was cardio-
vascular in nature, using ICD-9 codes 410 to 447.
Renal Transplant Characteristics
The Groningen Renal Transplant Database contains in-
formation about all renal transplantations that have been
performed at the University Medical Centre Groningen
since 1986, including dialysis history. Relevant transplant
characteristics, such as age and gender, were taken from
this database. Current medication was extracted from the
medical record. Presence of amputations, smoking status,
and CVD history were obtained using a self-report ques-
tionnaire. CVD history was considered positive if partici-
pants had a myocardial infarction, transient ischemic at-
tack, or cerebrovascular accident.
PA
PA data were estimated using the Tecumseh Occupa-
tional Activity Questionnaire (TOAQ) and the Minnesota
Leisure Time Physical Activity Questionnaire (MLTPAQ).
These questionnaires, taken by interview with trained re-
search assistants, estimate the total amount of PA over the
past 12 months. The TOAQ measures frequency, intensity,
and duration of a maximum of three occupation-related
activities within the previous 12 months. PAs associated
with transportation to work are also included. The TOAQ
is an acceptable measure of occupational PA energy expen-
diture and has been widely used (17). The MLTPAQ mea-
sures leisure time physical activities, including household
activities, over the previous 12 months. Both question-
naires have been extensively validated against the Caltrac
accelerometer, a PA record, and the doubly labeled water
method (18,19).
A combination of these two questionnaires was used to
estimate PA levels by using metabolic equivalents of task
(MET) (20,21). These questionnaires can be combined be-
cause they measure both intensity and duration of the
activity, which allows calculation summary scores in MET-
minutes per day (MET-min/d). MET-minutes are calcu-
lated by multiplying the intensity (indicated by the MET-
score) and the duration spent on that activity (measured in
minutes). The MET-score can be derived from tables (the
Compendium of Physical Activities) (22) that indicate the
intensity of the activity relative to resting. MET-minutes
spent on PA refer to the energy that is spend on activities,
over and above existing levels of resting energy expendi-
ture. Thus, if no notable PA is performed, PA will be
scored as 0 MET-min/d. This does not imply that there is
no energy expenditure, because resting energy expendi-
ture is not taken into account in the calculation of PA. The
combination of these questionnaires covers the whole of
physical activities during the day. A MET is a multiple of
daytime resting energy expenditure expressed in multiples
of 3.5 ml O2/kg per minute consumed, approximately
equaling the energy expenditure of an average adult at
rest, sitting quietly in a chair (18,22). For example, 1 MET
is the rate of energy expenditure while at rest, whereas
normal walking corresponds to a MET-score of 3.5 and
brisk walking to a MET-score of 5. If one would perform 1
hour of brisk walking per day as a single activity, the total
MET-min/d for PA would be 60  5  300 MET-min/d.
This means that during 1 hour of brisk walking, five times
more energy is spent than during 1 hour of resting.
In addition, it was assessed how many RTRs fulfilled the
most recent PA guideline (23). According to this guideline,
adults should do 2.5 h/wk of moderate-intensity PA,
which equals 30 minutes of moderate PA per day, for 5
d/wk. Because moderate PA corresponds to a MET-score
of 5 (brisk walking or mid-tempo cycling are typical exam-
ples), the guidelines correspond to 30  5  150 MET-
min/d for 5 d/wk.
Measurements and Definitions
Body mass index was determined as a measure of over-
all obesity. Waist circumference was measured on bare
skin midway between the iliac crest and the 10th rib.
Muscle mass was estimated by 24-hour urinary creatinine
excretion as described earlier (14). Twenty-four-hour uri-
nary creatinine excretion is considered a reliable measure
of muscle mass even in patients with advanced renal fail-
ure, in elderly people, and in patients with wasting condi-
tions (24–26). Blood was drawn after an overnight fasting
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period, which included no intake of medication, including
anti-hypertensive drugs and blood glucose–lowering med-
ication. BP was measured after a 6-minute rest in supine
position as the average of three automated measurements
at 1-minute intervals (Omron M4; Omron Europe).
Total cholesterol was determined using the cholesterol
oxidase-phenol aminophenazone method (MEGA AU 510;
Merck Diagnostica, Darmstadt, Germany), and serum trig-
lycerides were determined with the glycerol-3-phosphate
oxidase-phenol aminophenazone method. HDL-choles-
terol was determined with the cholesterol oxidase-phenol
aminophenazone method on a Technikon RA-1000 (Bayer
Diagnostics, Mijdrecht, The Netherlands), and LDL-choles-
terol was calculated using the Friedewald formula (21).
Plasma glucose was determined by the glucose-oxidase
method (YSI 2300 Stat plus; Yellow Springs). Serum high
sensitive C-reactive protein (hsCRP) was assessed with a
high sensitivity CRP ELISA assay. Serum and urine creat-
inine concentration were analyzed with a photometric
modification with the Jaffe´ method. Creatinine clearance
was calculated from 24-hour urinary creatinine excretion
and serum creatinine. Total urinary protein concentration
was analyzed using the Biuret reaction (MEGA AU 510;
Merck Diagnostica), and proteinuria was defined as uri-
nary protein excretion 0.5 g/24 h.
In this study, MS was defined by the definition of the
National Cholesterol Education Program Expert Panel (27).
Recently, the American Diabetes Association (ADA) low-
ered the cut-off point for impaired fasting glucose to 5.6
mmol/L (28). For our analysis of the prevalence of MS, we
used this ADA cut-off point. Diabetes was defined accord-
ing to the guidelines of the ADA as a fasting plasma
glucose 7.0 mmol/L or the use of anti-diabetic medica-
tion (29).
Statistical Analyses
Data were analyzed with SPSS version 16.0 (SPSS, Chi-
cago, IL) and GraphPad Prism version 4.03 (GraphPad
Software, San Diego, CA). Normally distributed variables
are expressed as mean  SD, whereas skewed distributed
variables are given as median (25th to 75th percentile);
percentages were used to summarize categorical variables.
Log transformation was used for variables with a skewed
distribution. Hazard ratios are reported with 95% confi-
dence interval.
Recipient-related characteristics were analyzed sepa-
rately for tertiles of PA level; predicted values are shown
adjusted for age. ANOVA or Kruskal-Wallis test was used
to compare means for continuous variables, with 2 for
categorical variables. To analyze whether PA is associated
with mortality, we first performed a Kaplan-Meier analy-
ses with a log-rank test.
Multivariate Cox regression analyses were performed to
study whether PA is independently associated with CV
and all-cause mortality. For these analyses MET-minutes
per day were first log transformed to achieve a normal
distribution and entered in the model as a continuous
variable. In multivariate Cox regression analyses, we first
adjusted for recipient age, gender (model 2), and history of
CV events (model 3). In addition to the adjustments for
age, gender, and history of CV events, we performed ad-
justment for insulin concentration, systolic BP, waist cir-
cumference, triglycerides, smoking, and hsCRP (model 4).
Similarly, we adjusted for Framingham risk score factors
(model 5), creatinine clearance and urinary protein excre-
tion (model 6), and 24-hour urinary creatinine excretion
(model 7).
We also studied potential interactions between PA and
24-hour urinary creatinine excretion as a measure for mus-
cle mass.
Results
A total of 540 RTRs were studied (mean age, 51 12 years;
54% men). Baseline characteristics according to gender-strat-
ified tertiles of PA of the RTRs are shown in Table 1. Because
PA was strongly inversely associated with age, we also ad-
justed the gender-stratified baseline characteristics for age.
Median values of PA over the tertiles were 4 [0 to 27], 115 [75
to 218], and 378 [234 to 514] MET-min/d, respectively. Me-
dian PA levels for women and men separately were 69 [4 to
171] MET-min/d in women and 204 [56 to 396] MET-min/d
(P  0.001) in men. With regard to the guidelines for mini-
mum requirements of PA, 260 (48%) of RTRs were not meet-
ing the criteria, and 79 (14.6%) were completely inactive, with
a PA score of 0 MET-min/d.
Independent of its relation to age, PA was inversely
associated with history of CVD, insulin concentration, trig-
lycerides, and hsCRP. Also independent of age, PA was
positively associated with creatinine clearance and urinary
creatinine excretion. Of the total of 540 patients, 364
(64.0%) fulfilled the criteria for MS. Prevalence of MS de-
creased from 135 (75%) to 118 (65.5%) and 111 (61.7%)
according to increasing tertiles of PA (P  0.007).
During follow-up for 5.3 [4.7 to 5.7] years, 81 recipients
died, with 37 deaths being CV in origin. Incidence of CV
death significantly decreased according to increasing ter-
tiles of PA, with respective numbers of 21 (11.7%), 13
(7.2%), and 3 (1.7%) (P  0.001; Figure 1A). A similar
association was present for all-cause mortality, with num-
bers of 50 (27.8%), 39 (21.7%), and 30 (16.7%) according to
increasing tertiles, respectively (P  0.001; Figure 1B).
RTRs with moderate PA levels (second tertile) already had
a lower risk for CV and all-cause mortality than inactive
RTRs (first tertile).
Results of univariate and multivariate Cox regression anal-
yses for associations of PA as a log-transformed continuous
variable with CV and all-cause mortality are presented in
Table 2. In univariate analyses, low PA strongly predicted
CV and all-cause mortality in RTRs (model 1). These asso-
ciations slightly weakened after adjustment for age and
gender (model 2). The same was true for adjustment for
history of CVD (model 3) and components of MS, smoking,
fasting insulin concentration, and hsCRP (model 4). In
model 5, adjustments were made for Framingham risk
score factors (30) (BP, LDL-cholesterol, HDL-cholesterol,
smoking, and presence of diabetes). Further adjustment for
renal function, urinary protein excretion, and 24-hour uri-
nary creatinine excretion as a measure of muscle mass
(models 6 and 7) did not materially change hazard ratios.
If analyses were repeated with either censoring at the
moment of return to dialysis of all RTRs who returned to
dialysis during follow-up (n  38) or exclusion of these
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RTRs, results of univariate and multivariate analyses re-
mained materially unchanged.
In multivariate Cox regression analyses, no interaction
between urinary creatinine excretion and PA was found.
Discussion
This study showed that low PA levels are strongly as-
sociated with CV and all-cause mortality in RTRs. To our
knowledge, this is the first study to report on PA level and
CV and all-cause mortality in these patients. This is con-
sistent with earlier findings in dialysis, CKD, and the gen-
eral population (8,9,31). Furthermore, it shows low levels
of PA are positively associated with CVD risk factors in
RTRs. Independent of age, PA was inversely associated
with history of CVD, presence of MS, fasting insulin con-
centration, and triglycerides, and positively associated
with kidney function and 24-hour urinary creatinine excre-
tion (as a measure of muscle mass).
We anticipated that a potential association of PA with
mortality could depend on risk factors for CVD, MS, or
smoking status. We found, however, that the association of
PA with mortality was not substantially affected by adjust-
ments for history of CV events, insulin concentrations,
components of the MS, or Framingham risk score factors.
The same holds for adjustments for renal function, despite
differences in creatinine clearance over the tertiles. An-
other anticipated confounder was the effect of muscle
mass, as reflected by 24-hour creatinine excretion, on the
association between PA and mortality. In a previous study,
we showed that muscle mass (as measured by 24-hour
creatinine excretion) is associated with mortality in RTRs
(12). Therefore, we speculated that low PA is associated
with low muscle mass and thereby with higher mortality.
Indeed, we now found that RTRs with higher PA also had
higher 24-hour creatinine excretion (i.e., larger muscle
mass). However, on multivariate analyses, PA was associ-
ated with CV and all-cause mortality independent of 24-
hour creatinine excretion. Based on the association be-
tween PA and mortality, it is tempting to speculate that
improvement of PA levels could contribute to improved
survival in RTRs.
PA may modulate CVD risk in several ways. Several
clinical studies in the general population showed that PA
lowers BP (32), improves body composition (33), lowers
triglycerides (34), and improves glucose tolerance and in-
sulin sensitivity (35,36). PA could modulate components of
Table 1. Baseline characteristics according to tertiles of physical activity
Tertiles of Physical Activitya
P
Inactive (n  180) Moderate (n  180) Active (n  180)
General characteristics
age (years) 56.1  11.0 51.6  11.8 46.0 11.5 0.001
smoking, n (%) 48 (26) 33 (18) 38 (21) 0.2
MS, n (%) 135 (75) 118 (70) 111 (62) 0.007
Cardiovascular disease
myocardial infarction, n (%) 21 (12) 13 (7) 9 (5) 0.06
transient ischemic attack/cerebrovascular
accident, n (%)
17 (10) 9 (5) 6 (3) 0.05
Body composition
body mass index (kg/m2) 26.3  4 25.8  4 26.0 4 0.7
waist circumference in women (cm) 96.6  14 93.2  14 92.4 14 0.1
waist circumference in men (cm) 100.4  12 98.2  12 100.3 12 0.4
urinary creatinine excretion (mmol/24 h) 10.7 10.3 to 1.2 11.4 10.9 to 11.9 12.5 11.9 to 13.1 0.001
Blood pressure
systolic BP (mmHg) 150  22 157  22 151 23 0.003
diastolic BP (mmHg) 89  10 92  10 90 10 0.04
anti-hypertensive medication, n (%) 164 (91) 149 (83) 158 (88) 0.08
use of ACE inhibitor, n (%) 65 (36) 50 (28) 70 (39) 0.09
use of -blocker, n (%) 119 (66) 108 (60) 108 (60) 0.5
Lipids and inflammation
total cholesterol (mmol/L) 5.65 1.1 5.59  1.1 5.61 1.1 0.89
HDL-cholesterol (mmol/L) 1.06 0.34 1.12  0.32 1.12 0.34 0.13
LDL-cholesterol (mmol/L) 3.6 1.0 3.5  1.0 3.6 1.0 0.7
triglycerides (mmol/L) 2.0 1.9 to 2.1 2.0 1.8 to 2.1 1.8 1.6 to 1.9 0.05
hsCRP (mg/L) 2.5 2.2 to 2.8 1.9 1.7 to 2.1 1.8 1.6 to 2.0 0.05
Glucose homeostasis
glucose (mmol/L) 5.0 1.4 4.8  1.4 4.8 1.4 0.4
insulin (mol/L) 12.7 11.7 to 13.8 11.2 10.3 to 12.1 10.2 9.4 to 11.1 0.001
diabetes mellitus, n (%) 36 (20) 31 (17) 27 (15) 0.4
Renal function
serum creatinine (mol/L) 141.6 135 to 149 137.1 131 to 144 136.5 130 to 143 0.6
creatinine clearance (ml/min) 53.1 50 to 56 57.8 55 to 61 63.4 60 to 67 0.001
urinary protein excretion (g/24 h) 0.36 0.3 to 0.4 0.35 0.3 to 0.4 0.32 0.3 to 0.4 0.8
proteinuria  0.5 g/24 h, n (%) 50 (28) 52 (29) 50 (28) 0.9
Data are represented as mean  SD or median 95% confidence interval. Differences were tested by ANOVA or Kruskal-Wallis test for continuous
variables and with 2 for categorical variables. ACE inhibitor, angiotensin converting enzyme inhibitor.
aTertiles of PA are stratified for gender and values are adjusted for age.
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the MS in RTRs in the same way as in the general popu-
lation, which is supported by our data. Most RTRs gain
substantial weight after transplantation, mainly because of
an increase in fat mass (37). Inactivity is strongly associated
with obesity, and consequently, with the accumulation of
visceral fat (38). Both visceral fat and physical inactivity
itself are associated with the activation of inflammatory
pathways (39), which in turn is involved in the cascade of
Figure 1. | (A) Kaplan-Meier curves of cardiovascular mortality according to gender-stratified tertiles of PA. *Adjusted for age (P  0.001).
(B) Kaplan-Meier curves of mortality according to gender-stratified tertiles of PA. *Adjusted for age (P  0.001).






HR 95% CI P HR 95% CI P
1 0.51 0.39 to 0.67 0.001 0.58 0.48 to 0.70 0.001
2 0.56 0.41 to 0.76 0.001 0.67 0.54 to 0.83 0.001
3 0.58 0.42 to 0.79 0.001 0.69 0.55 to 0.85 0.001
4 0.61 0.44 to 0.84 0.003 0.70 0.57 to 0.88 0.002
5 0.58 0.42 to 0.80 0.001 0.70 0.56 to 0.87 0.001
6 0.62 0.45 to 0.85 0.003 0.76 0.61 to 0.95 0.02
7 0.62 0.45 to 0.86 0.004 0.75 0.60 to 0.94 0.01
Model 1: Crude model of physical activity as a continuous variable (log-MET-min/day). Model 2: model 1  adjustment for age
and gender. Model 3: model 2  adjustment for history of cardiovascular events. Model 4: model 3  adjustment for insulin
concentration, systolic BP, waist circumference, triglycerides, smoking, and hsCRP. Model 5: model 3  adjustment for
Framingham risk score factors (BP, LDL-cholesterol, HDL-cholesterol, smoking, presence of diabetes). Model 6: model 5 
adjustment for creatinine clearance and urinary protein excretion. Model 7: model 5  adjustment for 24-hour urinary creatinine
excretion. HR, hazard ratio; CI, confidence interval.
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atherosclerosis and insulin resistance (40,41). The factors
above could partially explain the modulating effect of PA
on CVD risk.
Another mechanism that could elucidate the cardiopro-
tective effects of exercise is vascular adaptation. Physical
inactivity could lead to endothelial dysfunction in part by
reduced activity of vascular nitric oxide, an established
precursor to the atherosclerosis process (42,43). Exercise
training has been shown to increase nitric oxide produc-
tion, angiogenesis, and arteriogenesis and reduce vascular
oxidative stress; this could represent the response to exer-
cise that protects against CVD (43,44).
In our study, median energy expenditure attributable to
PA was 115 MET-min/d, with values of 69 MET-min/d for
women and 204 MET-min/d for men. Richardson et al. (18)
measured a mean energy expenditure of about 410 MET-
min/d in healthy subjects using the MLTPAQ, which only
measures leisure time physical activity. Thus, compared
with healthy subjects, RTRs have low PA levels in our
study, which is in line with two other studies in which
RTRs had lower levels of PA compared with healthy sub-
jects (45,46). A 5-year follow-up study showed that most
RTRs spontaneously became more active after transplan-
tation, which was associated with a better quality of life
(46). Although PA levels increase after transplantation,
they often remain relatively low (45,47).
There could be several reasons for the low levels of PA in
RTRs. Exercise capacity is approximately 30% lower in
RTRs than in controls (10). The main determinants of ex-
ercise capacity in RTRs are skeletal muscle strength and PA
level (47). It is difficult to determine whether low PA levels
are caused by low muscle mass or the other way around.
Before transplant, muscle mass is frequently low as a con-
sequence of muscle wasting associated with ESRD and
chronic hemodialysis (48). Metabolic acidosis and chronic
inflammation contribute to the process of muscle protein
degradation (48). After transplantation, chronic exposure
to corticosteroids can contribute to decreased muscle
mass. In line with this, we found in an earlier study that
cumulative prednisolone dose was inversely related to
muscle mass as reflected by 24-hour urinary creatinine
excretion (12). Thus, a primary lack in muscle mass may
impair RTRs in their capacity to exert PA. However, use
of corticosteroids has been shown to not limit the poten-
tial to build muscle mass and exercise capacity (47). It
has also been shown that disuse of muscle because of a
lack of PA can adversely affect muscle mass (13). It is
therefore obvious that to restore and maintain muscle
mass after transplantation, regular PA is needed. An-
other reason for inactivity may also be uncertainty about
being capable of being (and being allowed to be) phys-
ically active, with fear of injuring the graft playing a role
in this uncertainty.
Exercise studies in RTRs have indicated that exercise
training results in an improved exercise capacity, in-
creased muscle strength, improved BP control and bone
remodeling, and higher levels of self-reported physical
functioning (11,47). These results show that exercise
training in RTRs can be effective and feasible. Our re-
sults suggest that exercise training may benefit RTRs in
terms of better survival. In regular care after transplan-
tation, exercise training is not yet incorporated. Further
research is needed to study the role of PA intervention
after renal transplantation in the prevention and treat-
ment of CV risk factors, physical functioning, and long-
term outcome.
The strength of our study is its prospective design. RTRs
in this study were closely monitored by regular check-up
in our clinic, which allows for extensive information gath-
ering on patient status. A limitation of our study is that we
used questionnaires to measure PA. However, the ques-
tionnaires have been validated (17–19), and the RTRs were
interviewed by trained research assistants. Recall bias and
social desirability bias where the participants could tend to
report high volumes of PA are unfortunately unavoidable
and could influence internal validation. Validation studies
have shown that questionnaires may be effective in classi-
fying people into broad categories of PA (e.g., inactive,
moderate, and active) but are less appropriate for quanti-
fying absolute energy expenditure (49). Therefore, the fo-
cus in this study is not on absolute MET scores of PA but
on the ranking based on these scores. It is tempting to
speculate that stimulation of PA will improve outcome
after transplantation. This study is, however, observational
in design and not an intervention study; thus, hard con-
clusions on causality can not been drawn. We can not
exclude a more general effect of a more healthy lifestyle,
but our data support that PA contributes to a healthy
lifestyle pattern in RTRs.
In summary, low PA is an independent risk factor for CV
and all-cause mortality in RTRs. Our data suggest that
increased PA might have a CV survival benefit for RTRs.
Given the four to six times increased CVmortality in RTRs,
there is great potential for mortality reduction by exercise
participation in these patients.
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